Goldman Sachs
BNTC icon

Goldman Sachs’s Benitec Biopharma BNTC Stock Holding History

Goldman Sachs’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29M Buy
215,476
+41,435
+24% +$480K ﹤0.01% 4420
2025
Q4 		$2.34M Sell
174,041
-20,322
-10% -$281K ﹤0.01% 4432
2025
Q3 		$2.73M Buy
194,363
+173,369
+826% +$2.21M ﹤0.01% 4202
2025
Q2 		$246K Sell
20,994
-24,889
-54% -$348K ﹤0.01% 5555
2025
Q1 		$597K Buy
+45,883
New +$555K ﹤0.01% 5079

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Goldman Sachs's BNTC Position: Q1 2026 in Review

Goldman Sachs increased its Benitec Biopharma (BNTC) stake by 24% in Q1 2026, buying an estimated $480K and bringing the position to 215,476 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4420.

Goldman Sachs first reported a position in BNTC in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.73M in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Goldman Sachs held 215,476 shares of Benitec Biopharma worth $2.29M as of Q1 2026.
  • Goldman Sachs bought 41,435 Benitec Biopharma shares in Q1 2026, an estimated $480K.
  • Benitec Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4420 holding.
  • Goldman Sachs first reported a position in Benitec Biopharma in Q1 2025 and has held it in 5 quarters since.
  • Goldman Sachs's Benitec Biopharma position peaked at $2.73M in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.